Currently, few studies have reported the role of MAP1A in disease but have focused on MAP1A targeting therapy for nervous system diseases, including depression and Parkinson’s disease, the correlation between MAP1A gene expression and toxicity of HIV-1 infection-related immune diseases, as well as the degree of malignancy in brain glioma and prostate cancer (13–17). Here, MAP1A is linked to depressive disorder.